Cargando…

Comparison of the pharmacokinetics and pharmacodynamics of YH4808 in healthy subjects for defining an appropriate dosing regimen

YH4808 is a novel potassium-competitive acid blocker developed for gastric acid-related disorders. Previous studies indicate its potential to improve symptoms of gastric acid-related disorders. The current study was aimed to find the optimal regimen of YH4808 for night time pH control. This study wa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yoon, Sukyong, Oh, EunSil, Park, Min Soo, Jang, Seong Bok, Byun, Hae Mi, Park, Hyeonsoo, Kim, Heeyoung, Kim, Choon Ok
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Society for Clinical Pharmacology and Therapeutics 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8492394/ https://www.ncbi.nlm.nih.gov/pubmed/34621707 http://dx.doi.org/10.12793/tcp.2021.29.e15

Ejemplares similares

Pharmacodynamic evaluation of YH4808 for Helicobacter pylori eradication in healthy subjects
por: Park, Hyeonsoo, et al.
Publicado: (2020)

Evaluation of pharmacokinetic interactions between amoxicillin, clarithromycin, and the potassium-competitive acid blocker YH4808 in healthy subjects
por: Lee, Woo Yul, et al.
Publicado: (2020)

A population PK–PD model of YH4808, a novel P‐CAB, and intragastric pH that incorporated negative feedback by increased intragastric pH onto the systemic exposure to YH4808
por: Chung, Tae Kyu, et al.
Publicado: (2022)

A population pharmacokinetic‐pharmacodynamic model of YH12852, a highly selective 5‐hydroxytryptamine 4 receptor agonist, in healthy subjects and patients with functional constipation
por: Kim, Siun, et al.
Publicado: (2021)

Evaluation of pharmacokinetic interactions between lobeglitazone, empagliflozin, and metformin in healthy subjects
por: Kim, Heeyoung, et al.
Publicado: (2023)

Pharmacokinetics, pharmacodynamics and safety of CKD-519, a CETP inhibitor, in healthy subjects
por: Kim, Choon Ok, et al.
Publicado: (2016)

Complete Genome Sequences of Multidrug-Resistant Campylobacter coli Strains YH501, YH503, and YH504, from Retail Chicken
por: He, Yiping, et al.
Publicado: (2022)

A Population Pharmacokinetic and Pharmacodynamic Model of CKD-519
por: Kim, Choon Ok, et al.
Publicado: (2020)

Atrial Fibrilation in Practice: Gregory YH Lip
por: Nichols, D P
Publicado: (2002)

Pharmacokinetic and pharmacodynamic drug–drug interactions between evogliptin and empagliflozin or dapagliflozin in healthy male volunteers
por: Kim, Dasohm, et al.
Publicado: (2023)

The safety, pharmacodynamics, and pharmacokinetics of immediate-release formulation containing esomeprazole 20 mg/sodium bicarbonate 800 mg in healthy adult male
por: Kim, Dasohm, et al.
Publicado: (2019)

The YH database: the first Asian diploid genome database
por: Li, Guoqing, et al.
Publicado: (2009)

Complete Genome Sequence of Klebsiella pneumoniae YH43
por: Iwase, Tadayuki, et al.
Publicado: (2016)

A comparison of the pharmacokinetic and pharmacodynamic properties of nitroglycerin according to the composition of the administration set: A preliminary study
por: Kim, Choon Ok, et al.
Publicado: (2018)

YH12852, a Potent and Selective Receptor Agonist of 5‐hydroxytryptamine, Increased Gastrointestinal Motility in Healthy Volunteers and Patients With Functional Constipation
por: Lee, Hyun A., et al.
Publicado: (2020)

Selection of an appropriate empiric antibiotic regimen in hematogenous vertebral osteomyelitis
por: Park, Ki-Ho, et al.
Publicado: (2019)

Comparison of biosimilar filgrastim with a reference product: pharmacokinetics, pharmacodynamics, and safety profiles in healthy volunteers
por: Choi, Chungam, et al.
Publicado: (2018)

Evaluation of Amikacin Pharmacokinetics and Pharmacodynamics for Optimal Initial Dosing Regimen
por: Kato, Hideo, et al.
Publicado: (2017)

Nonsymmorphic symmetry protected node-line semimetal in the trigonal YH(3)
por: Shao, Dexi, et al.
Publicado: (2018)

Pharmacokinetic interactions between glimepiride and rosuvastatin in healthy Korean subjects: does the SLCO1B1 or CYP2C9 genetic polymorphism affect these drug interactions?
por: Kim, Choon Ok, et al.
Publicado: (2017)

Effect of Rifampicin on the Pharmacokinetics of Evogliptin in Healthy Volunteers
por: Shin, Yesong, et al.
Publicado: (2022)

Pharmacokinetic/pharmacodynamic modeling for the determination of a cimicoxib dosing regimen in the dog
por: Jeunesse, Elisabeth C, et al.
Publicado: (2013)

Novel Herbal Therapeutic YH23537 Improves Clinical Parameters in Ligature-Induced Periodontal Disease Model in Beagle Dogs
por: Shin, Jang-Woo, et al.
Publicado: (2023)

Clinical Use of Rivaroxaban: Pharmacokinetic and Pharmacodynamic Rationale for Dosing Regimens in Different Indications
por: Trujillo, Toby, et al.
Publicado: (2014)

Pharmacokinetics and pharmacodynamics of levofloxacin injection in healthy Chinese volunteers and dosing regimen optimization
por: Cao, G, et al.
Publicado: (2013)

Bayesian dose regimen assessment in early phase oncology incorporating pharmacokinetics and pharmacodynamics
por: Gerard, Emma, et al.
Publicado: (2021)

YH29407 with anti-PD-1 ameliorates anti-tumor effects via increased T cell functionality and antigen presenting machinery in the tumor microenvironment
por: Kim, Dong Kwon, et al.
Publicado: (2022)

Source gene composition and gene conversion of the AluYh and AluYi lineages of retrotransposons
por: Styles, Pamela, et al.
Publicado: (2009)

A novel protein kinase inhibitor IMB-YH-8 with anti-tuberculosis activity
por: Xu, Jian, et al.
Publicado: (2017)

Draft Genome Sequence of an Aldoxime Degrader, Rhodococcus sp. Strain YH3-3
por: Yamaguchi, Takuya, et al.
Publicado: (2016)

Population pharmacokinetics and pharmacodynamics of hydroxyurea in sickle cell anemia patients, a basis for optimizing the dosing regimen
por: Paule, Ines, et al.
Publicado: (2011)

Comparison of pharmacokinetics and safety of fixed-dose combination of SKI306X and aceclofenac versus separate tablets in healthy subjects
por: Meng, Xue, et al.
Publicado: (2017)

YH18968, a Novel 1,2,4-Triazolone G-Protein Coupled Receptor 119 Agonist for the Treatment of Type 2 Diabetes Mellitus
por: Han, Taedong, et al.
Publicado: (2018)

Association between prediabetes (defined by HbA1(C), fasting plasma glucose, and impaired glucose tolerance) and the development of chronic kidney disease: a 9-year prospective cohort study
por: Kim, Gwang Sil, et al.
Publicado: (2019)

Erratum to: Clinical Use of Rivaroxaban: Pharmacokinetic and Pharmacodynamic Rationale for Dosing Regimens in Different Indications
por: Trujillo, Toby, et al.
Publicado: (2014)

Rational dosage regimens for cephalothin and cefazolin using pharmacokinetics and pharmacodynamics analysis in healthy horses
por: Kuroda, Taisuke, et al.
Publicado: (2021)

Pharmacokinetics and Pharmacodynamics of Colistin Methanesulfonate in Healthy Chinese Subjects after Multi-Dose Regimen
por: Fan, Yaxin, et al.
Publicado: (2022)

ADME, Pharmacokinetic Scaling, Pharmacodynamic and Prediction of Human Dose and Regimen of Novel Antiviral Drugs
por: Chaira, Tridib, et al.
Publicado: (2023)

What Number of Oocytes Is Appropriate for Defining Poor Ovarian Response?
por: Kim, Seul Ki, et al.
Publicado: (2015)

On the potential of in vitro organ-chip models to define temporal pharmacokinetic-pharmacodynamic relationships
por: McAleer, Christopher W., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_etig8ae9otje5l65t9ddcjillu